Forward Pharma A/S, a Danish biotech developing a dimethyl fumarate (DMF) therapy for immune disorders, filed to raise up to $200 million in an initial public offering (IPO) that revealed at least one of the company's patents could conflict with a central claim protecting Biogen Idec Inc.'s Tecfidera, a fast-rising DMF-based multiple sclerosis (MS) therapy.